The U.S. Food and Drug Administration has placed a full clinical hold on late-stage clinical trials of Aardvark Therapeutics’ oral therapy candidate ARD-101 in patients with Prader-Willi syndrome (PWS) and hyperphagia, or insatiable hunger. The company had voluntarily paused…